Community/Retail

The life-saving opioid antagonist Narcan is playing a key role during a mass overdose in the Connecticut city.

health care reimbursements for medications in the United States are not consistently aligned with their value or net health benefits, according to a new study.

States that chose to expand Medicaid eligibility under the Affordable Care Act (ACA) have seen a greater decrease in uninsured rates among low-income patients with substance use disorders than states that did not expand Medicaid.

What to consider when considering a smart bottle program.

Researchers have developed a novel peptide drug called FFW that could potentially reduce tumor growth and slow progression of liver cancer.

Pharmacy Times® has launched a video tour of our updated website. Viewers are introduced to a variety of unique features, and will learn to access each of them.

The Mayo Clinic in Rochester, Minnesota, is at the top of the Best Hospitals ranking by U.S. News & World Report, and is included in the Top 5 lists for 3 selected specialties.

Vizuri Health Sciences’ PainBloc24®, a new topical analgesic product containing capsaicin, has arrived on the retail market.

The designation was based on data from 7 clinical trials over the past decade, which assessed omalizumab’s efficacy and safety versus various food allergens, such as peanut, milk, and egg.

Canine animal assistance improves attentiveness and social skills in children with ADHD, according to recent study.

The FDA has approved a combined hormonal contraceptive for women that is the first vaginal ring contraceptive that can be used for an entire year.

Officials with the FDA have approved the first targeted treatment for adult patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, a rare and often fatal disease.

The FDA has permitted marketing of Natural Cycles, the first mobile medical app that can be used as a method of contraception to prevent pregnancy.

As health care providers work to combat the growing abuse epidemic, the results of a new study suggest that interventions using behavioral insights can change the course of care.

This action, aimed at saving patients money, is part of the Trump administration’s larger agenda to create competition among medications that treat the same conditions.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The program recognizes over 30 exceptional pharmacy professionals in 10 categories.

The FDA has approved updates to the labeling for hepatitis C virus (HCV) drug glecaprevir and pibrentasvir (Mavyret) to include new data from 2 clinical studies.

The FDA has approved several strengths of Apotex Inc.’s potassium chloride oral solution as the first generic drugs to receive a Competitive Generic Therapy designation.

Officials with the FDA have approved a new treatment for 2 rare types of non-Hodgkin lymphoma of the skin, relapsed or refractory mycosis fungoides and Sézary syndrome, after at least 1 prior systemic therapy.

Ned Milenkovich, PharmD, JD, is chairman of the health care law practice at Much Shelist PC in Chicago, and former vice chairman of the Illinois State Board of Pharmacy. In this video, he discusses hemp regulation.

A recent study found that athletes with attention deficit hyperactivity disorder (ADHD) may need to be even more cautious in concussion prevention.

The agency has amended its list of drugs that contain the ingredient, which is used to treat high blood pressure and heart failure.

Officials with the FDA have updated the label of lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals), approving the treatment's use in children aged 2 to 5 years old.